Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience
F Martora, M Megna, T Battista, L Potestio… - Clinical, Cosmetic …, 2023 - Taylor & Francis
To date, adalimumab (ADA) is the only biotechnology drug approved for the management of
hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became …
hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became …
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
L Li, J Lu, J Liu, J Wu, X Zhang, Y Meng, X Wu… - Frontiers in …, 2024 - frontiersin.org
Psoriasis is a chronic autoimmune inflammatory disease characterized by erroneous
metabolism of keratinocytes. The development of psoriasis is closely related to abnormal …
metabolism of keratinocytes. The development of psoriasis is closely related to abnormal …
Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
Background Clinical trials have shown promising results for interleukin-23 inhibitors in the
treatment of psoriasis. The drugs have been used in clinical practice since 2017. Objective …
treatment of psoriasis. The drugs have been used in clinical practice since 2017. Objective …
The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
GE Fragoulis, S Siebert - Musculoskeletal Care, 2022 - Wiley Online Library
Abstract Background Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterised
by musculoskeletal and extra‐articular manifestations, most notably psoriasis. While the …
by musculoskeletal and extra‐articular manifestations, most notably psoriasis. While the …
Developmental drugs for sarcoidosis
Sarcoidosis is a multi-organ granulomatous inflammatory disease of unknown etiology. Over
50% of patients will require treatment at some point in their disease and 10%–30% will …
50% of patients will require treatment at some point in their disease and 10%–30% will …
[HTML][HTML] GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets
N Dand, PE Stuart, J Bowes, D Ellinghaus, J Nititham… - medRxiv, 2023 - ncbi.nlm.nih.gov
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have
identified biological mechanisms of psoriasis risk, including those targeted by effective …
identified biological mechanisms of psoriasis risk, including those targeted by effective …
Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and …
P Herranz-Pinto, ML Alonso-Pacheco… - Clinical Drug …, 2023 - Springer
Background Guselkumab is a drug used to treat moderate to severe plaque psoriasis.
However, real-life clinical data on its off-label use are limited, especially regarding the …
However, real-life clinical data on its off-label use are limited, especially regarding the …
Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis …
PJ Mease, A Ogdie, J Tesser, NJ Shiff, I Lin… - Rheumatology and …, 2023 - Springer
Introduction The aim of this work is to evaluate treatment persistence and clinical outcomes
after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active …
after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active …
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks
M Galluzzo, L Marcelli, L Vellucci… - Expert Opinion on …, 2023 - Taylor & Francis
Background Real-world data are useful to guide the management of psoriasis. Here, we
present data on the effectiveness and survival of guselkumab in moderate-to-severe chronic …
present data on the effectiveness and survival of guselkumab in moderate-to-severe chronic …
Increasing Access to Effective systemic treatments in patients with moderate-to-severe psoriasis: Narrative Review
Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence
ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with …
ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with …